Filing Flows

Filing Flows › Viridian Therapeutics (VRDN) › Next earnings date

Viridian Therapeutics (VRDN) earnings: beat the estimate

Viridian Therapeutics (VRDN) reported on Nov 4, 2026 and beat the EPS estimate: −$0.81 against −$1.02 (+20.7%). Revenue was $25.8M for Q3 2026, -64% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+20.7% vs estimate
Beat rate60%

The last report

Viridian Therapeutics reported revenue of $25.8M for the third quarter 2026 (-64% Y/Y), net loss $101M: Product revenue, net $24.7M, Collaboration revenue $956K, License revenue $125K. How it makes money → · Every quarter →

Viridian Therapeutics: EPS against the estimate, last 5 reportsViridian Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.94−$0.34Nov 25−$1.00−$1.08Feb 26−$1.08−$0.90May 26−$1.03−$1.05Aug 26−$1.02−$0.81Nov 26
Latest (Nov 26): Estimate −$1.02, Reported −$0.81.

Viridian Therapeutics' latest quarter

Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.

Questions

Did Viridian Therapeutics beat earnings?

Viridian Therapeutics (VRDN) reported on Nov 4, 2026 and beat the EPS estimate: −$0.81 against −$1.02 (+20.7%).

When does VRDN report earnings?

The next date is not set yet.

Does Viridian Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.